Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 12 , Pages 1369-1374 , December 2008

Recent NIMH Clinical Trials and Implications for Practice

  • Christopher J. Kratochvil, M.D. (Assistant Editor)
    • ,
  • Benedetto Vitiello, M.D.

      Affiliations

    • Corresponding Author InformationCorrespondence to Benedetto Vitiello, M.D., National Institute of Mental Health, Room 7147, 6001 Executive Blvd., Bethesda, MD 20892-9633

,Accepted 9 July 2008.

References 

  1. Vitiello B , Jensen PS . Medication development and testing in children and adolescents . Arch Gen Psychiatry . 1997;54:871–876
  2. RUPP Anxiety Study Group  . Fluvoxamine for the treatment of anxiety disorders in children and adolescents . N Engl J Med . 2001;344:1279–1285
  3. RUPP Autism Network  . Risperidone in children with autism and serious behavioral problems . N Engl J Med . 2002;347:314–321
  4. TADS Team . Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression . JAMA . 2004;292:807–820
  5. TADS Team . The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes . Arch Gen Psychiatry . 2007;64:1132–1144
  6. Brent D , Emslie G , Clarke G , et al.   The Treatment of Adolescents with SSRI-Resistant Depression (TORDIA): a comparison of switch to venlafaxine or to another SSRI, with or without additional cognitive behavioral therapy . JAMA . 2008;299:901–913
  7. Pediatric Obsessive-Compulsive Treatment Study  . Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial . JAMA . 2004;292:1969–1976
  8. Kollins SH , Greenhill IX , Swanson S , et al.   Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS) . J Am Acad Child Adolesc Psychiatry . 2006;45:1275–1283
  9. Greenhill LL , Abikoff H , Chuang S , et al.   Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD . J Am Acad Child Adolesc Psychiatry . 2006;45:1284–1293
  10. Wigal T , Greenhill LL , Chuang S , et al.   Safety and tolerability of methylphenidate in preschool children with ADHD . J Am Acad Child Adolesc Psychiatry . 2006;45:1294–1303
  11. Vitiello B , Abikoff HB , Chuang SZ , et al.   Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-deficit/hyperactivity disorder Treatment Study (PATS) . J Child Adolesc Psychopharmacol . 2007;17:593–603
  12. Swanson J , Greenhill L , Wigal T , et al.   Stimulant-related reductions of growth rates in the PATS . J Am Acad Child Adolesc Psychiatry . 2006;45:1304–1313
  13. RUPP Autism Network  . A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders and hyperactivity . Arch Gen Psychiatry . 2005;62:1266–1274
  14. Emslie GJ , Rush AJ , Weinberg WA , et al.   A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression . Arch Gen Psychiatry . 1997;54:1031–1037
  15. Brent DA , Holder D , Kolko D , et al.   A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy . Arch Gen Psychiatry . 1997;54:877–885
  16. Kratochvil CJ , Emslie GJ , Silva SG , et al.   Time to response for depressed adolescents receiving fluoxetine, cognitive-behavioral therapy, or combined treatment . J Am Acad Child Adolesc Psychiatry . 2006;45:1412–1418
  17. Kennard BD , Silva S , Vitiello B , et al.   Remission and residual symptoms after acute treatment of adolescents with major depressive disorder . J Am Acad Child Adolesc Psychiatry . 2006;45:1404–1411
  18. Vitiello B , Rohde P , Silva SG , et al.   Effects of treatment on level of functioning, global health, and quality of life in depressed adolescents . J Am Acad Child Adolesc Psychiatry . 2006;45:1419–1426
  19. Emslie GJ , Kratochvil CJ , Vitiello B , et al.   Treatment for Adolescents with Depression Study (TADS): safety results . J Am Acad Child Adolesc Psychiatry . 2006;45:1440–1455
  20. Domino M , Burns BJ , Silva SG , et al.   The cost-effectiveness of treatments for adolescent depression: results from the TADS randomized trial . Am J Psychiatry . 2008;165:588–596
  21. Goodyer I , Dubicka B , Wilkinson P , et al.   Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomized controlled trial . BMJ . 2007;335:142
  22. Clarke G , DeBar L , Lynch F . A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication . J Am Acad Child Adolesc Psychiatry . 2005;44:888–898
  23. Rush AJ . STAR*D: what have we learned? . Am J Psychiatry . 2007;164:201–214
  24. American Academy of Child and Adolescent Psychiatry  . Practice parameter for the assessment and treatment of children and adolescents with depression disorders . J Am Acad Child Adolesc Psychiatry . 2007;46:1503–1526
  25. American Academy of Child and Adolescent Psychiatry  . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder . J Am Acad Child Adolesc Psychiatry . 2007;46:894–921
  26. Hammad TA , Laughren T , Racoosin J . Suicidality in pediatric patients treated with antidepressant drugs . Arch Gen Psychiatry . 2006;63:332–339
  27. Bhatia SK , Rezac AJ , Vitiello B , Sitorius MA , Buehler BA , Kratochvil CJ . Antidepressant prescribing practices for the treatment of children and adolescents . J Child Adolesc Psychopharmacol . 2008;18:70–80

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacobgical management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision making.The opinions and assertions contained in this article are the private views of the author and are not to be construed as official or as reflecting the views of the Department of Health and Human Services, the National Institutes of Health, or the National Institute of Mental Health.

PII: S0890-8567(08)60135-5

doi: 10.1097/CHI.0b013e31818960a7

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 12 , Pages 1369-1374 , December 2008

Article Tools